Annual General Shareholders Meeting

Today, we held our Annual General Meeting of Shareholders, reflecting on our continued momentum and steady progress toward our ambition of becoming a global leader in medical dermatology. The meeting provided an update on our performance, strategic priorities, and the key drivers shaping our growth trajectory.

Our strong performance is driven by the solid evolution of our European Dermatology business and the continued expansion of our biologics portfolio. These pillars, together with the advancement of our R&D pipeline, are reinforcing our position and supporting long-term value creation.

A key highlight of the meeting was our transition into a new phase of sustained double-digit growth and margin expansion starting in 2025. This progress reflects our continuous investment in strengthening capabilities across the entire value chain—from research and development to manufacturing and commercial operations—enabling consistent performance and building a strong foundation for future growth.

Looking ahead, we are well positioned to maintain this momentum, supported by a robust pipeline and important R&D milestones expected throughout the year. These advancements will continue to drive innovation and bring new solutions to patients.

The meeting also underscored our commitment to our purpose of transforming the lives of people living with skin conditions. By combining scientific excellence, innovation, and a clear strategic focus, we continue to advance medical dermatology while delivering sustainable growth.

We thank our shareholders for their continued trust and support, which remain key to advancing our long-term vision.